𝔖 Bobbio Scriptorium
✦   LIBER   ✦

10 HBV-DNA markers predictive of response to lamivudine (LAM) therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B

✍ Scribed by A. Ciancio; A. Smedile; M. Rizzetto; M. Lagget; A. Olivero; M.L. Abate; J. Gerin; B. Korba

Book ID
119631692
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
151 KB
Volume
35
Category
Article
ISSN
1590-8658

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60